New Ways to Predict TAVR Outcomes for Individual Heart Patients

Why It Matters

Accurate, inexpensive risk stratification can steer clinicians toward the right candidates, potentially lowering complications and improving survival rates in an aging, high‑risk population.

Key Takeaways

• CALLY index predicts 19.8% mortality with AUC 0.698
• Low CALLY score independently raises post‑TAVR death risk
• Study analyzed 300+ patients over 21‑month follow‑up
• AI CT body‑composition links low muscle to higher 3‑year mortality
• Over 2,500 TAVR cases confirm imaging biomarkers for long‑term risk

Pulse Analysis

Transcatheter aortic valve replacement has become the go‑to therapy for severe aortic stenosis, yet clinicians still grapple with identifying patients who may face adverse outcomes. Traditional risk scores focus on age, comorbidities, and procedural factors, but they often overlook the nuanced interplay of systemic inflammation and nutritional status. Emerging biomarkers like the C‑reactive protein‑albumin‑lymphocyte (CALLY) index fill this gap by offering a composite view of a patient’s inflammatory burden and protein reserves, both of which are known to influence cardiovascular recovery. By leveraging routine lab data, the CALLY index provides a cost‑effective, bedside tool that can be integrated into existing electronic health records.

The Turkish cohort study, encompassing more than 300 TAVR recipients with a median follow‑up of 21 months, demonstrated that a low CALLY score independently predicts all‑cause mortality, achieving an area under the ROC curve of 0.698. This performance rivals more complex, expensive panels while remaining accessible to community hospitals. The findings suggest that clinicians could flag high‑risk individuals before the procedure, prompting intensified monitoring, nutritional interventions, or alternative therapeutic pathways. However, the retrospective design underscores the need for prospective validation across diverse populations before widespread adoption.

Parallel research at the Mayo Clinic harnessed artificial‑intelligence‑driven analysis of pre‑procedure CT angiography to quantify skeletal muscle, subcutaneous, visceral, and intermuscular fat. In a sample of over 2,500 patients, reduced muscle mass and adipose tissue indices correlated with a significantly higher three‑year mortality risk. Because CT imaging is already standard in TAVR planning, extracting body‑composition metrics adds no extra radiation or cost, yet it enriches the clinical picture with actionable prognostic data. Future multicenter trials will be crucial to confirm generalizability, but the convergence of biomarker science and AI imaging heralds a new era of personalized, data‑rich decision‑making in structural heart disease.